

Amendments to the Claims

The listing of claims set forth below will replace all prior versions and listings of claims in the application.

1-37 (Canceled).

38. (Currently Amended) A method of treating ~~or preventing~~ the inflammatory response of ulcerative colitis in a subject comprising administering to the subject an effective amount of a substance ~~that modulates NK-T cell activity that binds NK-T cells or antigen presenting cells and reduces the number of NK-T cells in the subject or inhibits NK-T cell activation by antigen presenting cells.~~

39. (Previously Presented) The method of claim 38, wherein the substance modulates NK-T cell activity by reducing NK-T cell activity.

40. (Previously Presented) The method of claim 38, wherein the substance modulates NK-T cell activity by maintaining a level of NK-T cell activity.

41. (Previously Presented) The method of claim 38, wherein the subject is a mouse.

42. (Previously Presented) The method of claim 38, wherein the subject is a human.

43-44 (Canceled)

45. (Currently Amended) The method of claim 38, wherein the ulcerative colitis is oxazolone colitis.

46. (Currently Amended) The method of claim 38, wherein the substance ~~that modulates NK-T cell activity~~ is an antibody.

47-48 (Canceled)

49. (Withdrawn) The method of ~~claim 47~~claim 46, wherein the antibody binds to CD1.

50. (Withdrawn) The method of ~~claim 47~~claim 46, wherein the antibody binds to V α 14 J α 281.

51. (Withdrawn) The method of ~~claim 47~~claim 46, wherein the antibody binds to V α 24 J α 18.

52. (Currently Amended) A method of treating ~~or preventing~~ the inflammatory response of ulcerative colitis in a subject comprising administering to the subject an effective amount

of a substance that ~~modulates IL-13 activity~~ a substance that binds to IL-13, wherein the substance inhibits IL-13 activation of IL-13R α .

53-64 (Canceled)

65. (Previously Presented) The method of claim 52, wherein the subject is a mouse.

66. (Previously Presented) The method of claim 52, wherein the subject is a human.

67-68 (Canceled)

69. (Currently Amended) The method of claim 52, wherein the ulcerative colitis is oxazolone colitis.

70. (Canceled)

71. (Currently Amended) The method of claim 52, wherein the substance that binds to ~~modulates IL-13 activity~~ is an antibody.

72. (Withdrawn) The method of claim 52, wherein the substance binds to IL-13 is IL-13 α Ra2-Fc.

73-74 (Canceled)

75. (Withdrawn) A method of screening a substance for effectiveness in reducing the inflammatory response of ulcerative colitis by ~~inhibiting modulating~~ NK-T cell activity comprising:

- a) obtaining an animal having ulcerative colitis;
- b) administering the substance to an animal;
- c) assaying the animal for an effect on NK-T cell activity which results in the reduction of the inflammatory response of the ulcerative colitis, thereby identifying a substance effective in reducing the inflammatory response of ulcerative colitis by ~~inhibiting modulating~~ NK-T cell activity.

76. (Withdrawn) The method of claim 75, wherein the animal is a mouse.

77. (Canceled)

78. (Withdrawn) The method of claim 75, wherein the animal has an established ulcerative colitis produced by introducing into the colon of the animal an effective amount of a hapten reagent.

79. (Withdrawn) The method of claim 75, wherein the hapten reagent is oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one).
80. (Withdrawn) The method of screening a substance for effectiveness in reducing the inflammatory response of ulcerative colitis by ~~inhibiting~~ modulating IL-13 activity comprising:
- a) obtaining an animal having ulcerative colitis;
 - b) administering the substance to an animal;
 - c) assaying the animal for an effect on IL-13 activity which results in the reduction of the inflammatory response of the ulcerative colitis, thereby identifying a substance effective in reducing the inflammatory response of ulcerative colitis by inhibiting ~~modulating~~ IL-13 activity.
81. (Withdrawn) The method of claim 80, wherein the animal is a mouse.
82. (Canceled)
83. (Withdrawn) A method of screening for a substance effective in preventing the inflammatory response of ulcerative colitis by ~~inhibiting~~ modulating IL-13 activity comprising:
- a) administering the substance to an animal susceptible to ulcerative colitis;
 - b) subjecting the animal to treatment that will induce an inflammatory response; and
 - c) assaying inflammatory tissue cells from the animal for an amount of secretion of IL-13, whereby a decrease or lack of increase in the amount of IL-13 in the inflammatory tissue cells of the animal as compared to an increase in the amount of IL-13 in a control animal having ulcerative colitis in the absence of the substance identifies a substance that is effective in preventing the inflammatory response of ulcerative colitis by inhibiting ~~modulating~~ IL-13 activity.
84. (Withdrawn) A method of screening for a substance effective in preventing the inflammatory response of ulcerative colitis by ~~inhibiting~~ modulating NK-T cell activity comprising:
- a) administering the substance to an animal susceptible to ulcerative colitis;
 - b) subjecting the animal to treatment that will induce an inflammatory response; and

- c) assaying the animal for an effect on NK-T cell activity, whereby a decrease or lack of increase in NK-T cell activity in the inflammatory tissue cells of the animal as compared to an increase in NK-T cell activity in a control animal having ulcerative colitis in the absence of the substance identifies a substance that is effective in preventing the inflammatory response of ulcerative colitis by inhibiting ~~modulating~~ NK-T cell activity.
85. (New) The method of claim 52, wherein the method further comprises administering to the subject an effective amount of an antibody that binds to IL-13R α 2.